Novel CIL-102 Derivatives as Potential Therapeutic Agents for Docetaxel-Resistant Prostate Cancer

In this study, we modified the structure of CIL-102 and investigated the efficacy of the derivatives against CRPC and docetaxel-resistant PCa.

Source: Cancer Letters - August 2, 2018 Category: Cancer & Oncology Authors: Dannah R. Miller, Cherng-Chyi Tzeng, Trey Farmer, Evan T. Keller, Steve Caplan, Yu-Shuin Chen, Yeh-Long Chen, Ming-Fong Lin Tags: Original Articles Source Type: research